中国药业2025，Vol.34Issue(16)：39-43,5.DOI:10.3969/j.issn.1006-4931.2025.16.007
国家医保谈判背景下我国免疫检查点抑制剂可获得性、可负担性及药物利用现状评价
Evaluation of the Availability,Affordability and Drug Utilization Status of Immune Checkpoint Inhibitors in China Under the Background of National Medical Insurance Negotiations
摘要
Abstract
Objective To understand the accessibility,affordability,and current drug utilization status of immune checkpoint inhibitors(ICIs)in China under the background of the National Medical Insurance Negotiations(hereinafter referred to as ″Guo Tan″).Methods The National Pharmaceutical Information Network of the Chinese Pharmaceutical Association was used to search for quarterly procurement data of ICIs from 859 secondary(292 hospitals)or tertiary(567 hospitals)public comprehensive hospitals in 31 provincial-level administrative regions(excluding Hong Kong,Macao,and Taiwan)in China from 2019 to 2023.Descriptive statistical analysis was conducted using drug utilization evaluation indicators such as availability,affordability,defined daily doses(DDDs),and defined daily dose cost(DDDc).Results A total of 16 listed ICIs were included,and the availability rate of each ICI in tertiary hospitals(up to 63.32%)was significantly higher than that in secondary hospitals(up to 35.83%).As of January 2023,four types of ICIs were entered the ″Guo Tan″ list,and their availability rates were generally higher than various non ″Guo Tan″ drugs(all below 20%),among which the availability rates of Sintilimab,Carmrelizumb,and Tislelizumab were higher in tertiary hospitals.The overall affordability of various ICIs showed slow upward trend,and the annual usage amount of various ICIs was increasing year by year,with more significant increase in the ″Guo Tan″ ICIs.Compared to those in 2019,the DDDs of various ICIs in 2023 were almost doubled.The DDDc of ″Guo Tan″ ICIs showed a decreased trend year by year(with an average decrease was 81.55%as of 2023).Conclusion The implementation of the ″Guo Tan″ policy can improve the accessibility and increase the use of ICIs in hospitals.This study can provide data support for the optimization and adjustment of relevant policies in the future.关键词
免疫检查点抑制剂/国家医保谈判/可获得性/可负担性/药物利用评价Key words
immune checkpoint inhibitors/National Medical Insurance Negotiations/accessibility,affordability/drug utilization evaluation分类
医药卫生引用本文复制引用
郭伟,史海艳,张晗,李伟,林彦全,陆伟,陈红斗..国家医保谈判背景下我国免疫检查点抑制剂可获得性、可负担性及药物利用现状评价[J].中国药业,2025,34(16):39-43,5.基金项目
江苏省新药研究与临床药学重点实验室开放研究课题[KFKT-2305]. （）
